Targeting Tumor-Associated Immune Cells with RNAi-Lipid Conjugates
Time: 9:00 am
day: Conference Day One
Details:
- Refractory malignant solid tumors create an immunosuppressive TME which renders them resistant to standard-of-care immune checkpoint inhibitors
- How RNAi agents can silence CD274 (PD-L1) in tumor-associated immune cells, which mediate immune suppression in the TME
- Silencing Cd274 in antigen presenting cells remodeled the TME, increased cytotoxic T-cell infiltration and mediated single agent activity in immunotherapy resistant preclinical tumors. Human active PDL1 RNAi is in currently in Phase 1 clinical trials for immunotherapy-refractory cancers (NCT06504368)
NEW DATA
